The Q1 Margin Beat: Old Inventory, Unproven Pricing

Q1 EBITDA margin of 27% (₹194 Cr on ₹681 Cr revenue) beat prior guidance of ~20%, but the quarter rode an internal tailwind. Needle coke costs have risen $200–300/ton since Middle East disruptions, yet Q1 was manufactured from 3–4 month old inventory at legacy prices. By November, new shipments at elevated cost will flow through the P&L. Simultaneously, Q1's +7–8% pricing realization was already locked in by bookings made before the call; October onwards remains unproven. Management is guiding price hikes to offset cost inflation, but refuses to quantify the magnitude, leaving steelmaker acceptance as the open question.

Management effectively upgraded margin guidance (27% Q1 delivered vs prior ~20% two-quarter target, now targeting 28–29% maintenance), yet the upgrade's permanence hinges on a single unquantified pivot in October. Competitor pricing announcements — GrafTech $600–1,200/ton, Tokai $930/ton — are now public domain knowledge, raising steelmaker awareness and their negotiating hand. On the structural demand side, OECD EAF roadmap reinforced: 71M tons planned by end 2028 vs. 25–30M already commissioned in FY24–25, a substantial yet contested build-out. TACC anode execution on schedule: 70% of 20,000-ton capacity pre-sold by September close, commercial ramp FY28, diversifying HEG beyond electrodes into higher-margin anode production.

Post-result price action has been deliberate and holding, not a fade. Initial +4.17% move on day 1 built to +8.96% by day 3, settling at +12.32% by day 5—a sustained conviction rather than a pop-and-drop. Stock now ₹657.25, sitting -4.14% from its all-time high of ₹685.65 but +39.57% from the 52-week low, trading firmly above SMA20 (₹597), SMA50 (₹564), and SMA200 (₹558)—a bullish technicals backdrop. RSI 71.8 signals overbought, constraining near-term upside without fresh catalyst. On the ownership tape, FII have been adding (QoQ +1.71pp to 10.24%), while DII have trimmed (-3.52pp to 8.62%), a textbook pattern of foreign institutions betting on the structural thesis while domestic money takes profit. The April block deal (₹10 Cr by GDN Ventures @ ₹631) was unrelated to promoters, just routine secondary activity. Overall, the street has priced in the Q1 beat and the structural EAF tailwind; the October pricing absorption window will determine whether the rally has legs.

Q1 was a genuine beat — 27% EBITDA margin, ₹681 Cr revenue (+11% YoY), 90%+ utilization sustained. But the margin rested on two near-term tailwinds: (1) old needle coke inventory priced 3–4 months ago, carrying forward at legacy cost, and (2) pricing realization of +7–8% already locked in by Q1 bookings. Neither tailwind repeats in Q2. Starting October, management guides price increases as competitor announcements go public ($600–1,200/ton), but steelmaker acceptance is unproven in a global environment where Western competitor utilization is only 60–65%—signaling excess capacity to undercut. Needle coke costs will rise $200–300/ton by November as new shipments work through the P&L. For HEG to hit its 28–29% margin target, October price hikes must not only stick but exceed the $200–300/ton input inflation—a narrow, contested window. The structural bull case remains sound: 71M-ton EAF capacity planned by 2028, HEG's 100,000-ton scale, 4+ year 90%+ utilization track record, and ₹858 Cr debt-free treasury all support durable long-term positioning. But the next two quarters are a near-term execution test under significant cost pressure. This is not a step-change in profitability; it is steady execution contested by input inflation and competitive dynamics. The number to track is Q2–Q3 EBITDA margin: 28–29% validates the consensus trajectory; 26–27% signals competitive price wars are eroding margin gains.